Literature DB >> 23576269

The PIM family of serine/threonine kinases in cancer.

Maja Narlik-Grassow1, Carmen Blanco-Aparicio, Amancio Carnero.   

Abstract

The proviral insertion site in Moloney murine leukemia virus, or PIM proteins, are a family of serine/threonine kinases composed of three different isoforms (PIM1, PIM2, and PIM3) that are highly evolutionarily conserved. These proteins are regulated primarily by transcription and stability through pathways that are controlled by Janus kinase/Signal transducer and activator of transcription, JAK/STAT, transcription factors. The PIM family proteins have been found to be overexpressed in hematological malignancies and solid tumors, and their roles in these tumors were confirmed in mouse tumor models. Furthermore, the PIM family proteins have been implicated in the regulation of apoptosis, metabolism, cell cycle, and homing and migration, which has led to the postulation of these proteins as interesting targets for anticancer drug discovery. In the present work, we review the importance of PIM kinases in tumor growth and as drug targets.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  PIM kinases; cancer; oncogenes

Mesh:

Substances:

Year:  2013        PMID: 23576269     DOI: 10.1002/med.21284

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  81 in total

1.  Pim1 kinase promotes angiogenesis through phosphorylation of endothelial nitric oxide synthase at Ser-633.

Authors:  Ming Chen; Bing Yi; Ni Zhu; Xin Wei; Guan-Xin Zhang; Shengdong Huang; Jianxin Sun
Journal:  Cardiovasc Res       Date:  2015-11-23       Impact factor: 10.787

2.  Alpinumisoflavone induces apoptosis in esophageal squamous cell carcinoma by modulating miR-370/PIM1 signaling.

Authors:  Yantao Han; Xiuwei Yang; Ning Zhao; Jianjun Peng; Hui Gao; Xia Qiu
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

3.  PIM1 induces cellular senescence through phosphorylation of UHRF1 at Ser311.

Authors:  J Yang; K Liu; J Yang; B Jin; H Chen; X Zhan; Z Li; L Wang; X Shen; M Li; W Yu; Z Mao
Journal:  Oncogene       Date:  2017-04-10       Impact factor: 9.867

4.  The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival.

Authors:  Laura L Stafman; Mary G Waldrop; Adele P Williams; Jamie M Aye; Jerry E Stewart; Elizabeth Mroczek-Musulman; Karina J Yoon; Kimberly Whelan; Elizabeth A Beierle
Journal:  J Pediatr Surg       Date:  2019-02-28       Impact factor: 2.545

5.  Resibufogenin suppresses tumor growth and inhibits glycolysis in ovarian cancer by modulating PIM1.

Authors:  Qian Li; Chuanwu Jiang; Yan Wang; Minghua Wei; Huijin Zheng; Yanqi Xu; Xuegang Xu; Fengyu Jia; Kai Liu; Gang Sun; Jianhua Zang; Ping Mo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-07-10       Impact factor: 3.000

6.  Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.

Authors:  Lisa S Chen; Ji-Yeon Yang; Han Liang; Jorge E Cortes; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2016-04-07

7.  Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer.

Authors:  Yu-Qian Zhao; Yi-Qiong Yin; Jie Liu; Gui-Hua Wang; Jian Huang; Ling-Juan Zhu; Jin-Hui Wang
Journal:  Acta Pharmacol Sin       Date:  2016-07-11       Impact factor: 6.150

8.  Serine threonine kinase Pim-3 regulates STAT3 pathway to inhibit proliferation of human liver cancers.

Authors:  Jianqiang Wang; Lijun Lao; Hui Zhao; Yuan Huang
Journal:  Int J Clin Exp Med       Date:  2014-02-15

Review 9.  PIM1: a promising target in patients with triple-negative breast cancer.

Authors:  Wen Zhao; RuiYue Qiu; Pan Li; Jin Yang
Journal:  Med Oncol       Date:  2017-07-18       Impact factor: 3.064

Review 10.  Rapamycin-resistant effector T-cell therapy.

Authors:  Daniel H Fowler
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.